These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 38233727)

  • 1. Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy.
    Singh V; Nandi S; Ghosh A; Adhikary S; Mukherjee S; Roy S; Das C
    Cancer Metastasis Rev; 2024 Mar; 43(1):175-195. PubMed ID: 38233727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.
    Saleh R; Toor SM; Sasidharan Nair V; Elkord E
    Front Immunol; 2020; 11():1469. PubMed ID: 32760400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy.
    Dai E; Zhu Z; Wahed S; Qu Z; Storkus WJ; Guo ZS
    Mol Cancer; 2021 Dec; 20(1):171. PubMed ID: 34930302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetics and immunotherapy: The current state of play.
    Dunn J; Rao S
    Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differentiation and Regulation of T
    Basu A; Ramamoorthi G; Albert G; Gallen C; Beyer A; Snyder C; Koski G; Disis ML; Czerniecki BJ; Kodumudi K
    Front Immunol; 2021; 12():669474. PubMed ID: 34012451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining epigenetic and immune therapy to overcome cancer resistance.
    Gomez S; Tabernacki T; Kobyra J; Roberts P; Chiappinelli KB
    Semin Cancer Biol; 2020 Oct; 65():99-113. PubMed ID: 31877341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.
    Yang J; Xu J; Wang W; Zhang B; Yu X; Shi S
    Signal Transduct Target Ther; 2023 May; 8(1):210. PubMed ID: 37217462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2, a prominent orchestrator of genetic and epigenetic regulation of solid tumor microenvironment and immunotherapy.
    Sun S; Yu F; Xu D; Zheng H; Li M
    Biochim Biophys Acta Rev Cancer; 2022 Mar; 1877(2):188700. PubMed ID: 35217116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic Reprogramming of CD4
    Renaude E; Kroemer M; Borg C; Peixoto P; Hervouet E; Loyon R; Adotévi O
    Front Immunol; 2021; 12():669992. PubMed ID: 34262562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point?
    Liu J; Zhang B; Zhang G; Shang D
    Front Immunol; 2024; 15():1345838. PubMed ID: 38449875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic modulation in cancer immunotherapy.
    Gallagher SJ; Shklovskaya E; Hersey P
    Curr Opin Pharmacol; 2017 Aug; 35():48-56. PubMed ID: 28609681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.
    Peng D; Kryczek I; Nagarsheth N; Zhao L; Wei S; Wang W; Sun Y; Zhao E; Vatan L; Szeliga W; Kotarski J; Tarkowski R; Dou Y; Cho K; Hensley-Alford S; Munkarah A; Liu R; Zou W
    Nature; 2015 Nov; 527(7577):249-53. PubMed ID: 26503055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications.
    Yin J; Gu T; Chaudhry N; Davidson NE; Huang Y
    Front Immunol; 2023; 14():1325615. PubMed ID: 38268926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conserved methylation signatures associate with the tumor immune microenvironment and immunotherapy response.
    Qin Q; Zhou Y; Guo J; Chen Q; Tang W; Li Y; You J; Li Q
    Genome Med; 2024 Apr; 16(1):47. PubMed ID: 38566132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy.
    Liu M; Zhou J; Chen Z; Cheng AS
    J Pathol; 2017 Jan; 241(1):10-24. PubMed ID: 27770445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doxorubicin induced epigenetic regulation of dendritic cell maturation in association with T cell activation facilitates tumor protective immune response in non-small cell lung cancer (NSCLC).
    Mukherjee O; Paul S; Das S; Rakshit S; Shanmugam G; George M; Sarkar K
    Pathol Res Pract; 2024 Jan; 253():155004. PubMed ID: 38086291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunological hide-and-seek: epigenetically reprogrammed cancer cells and the dynamics of CD8
    Low JT; Chan MWY; Shen CH; Wei KL
    Mol Biol Rep; 2024 Sep; 51(1):959. PubMed ID: 39230620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy.
    Loo Yau H; Ettayebi I; De Carvalho DD
    Trends Cell Biol; 2019 Jan; 29(1):31-43. PubMed ID: 30153961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD8
    Farhood B; Najafi M; Mortezaee K
    J Cell Physiol; 2019 Jun; 234(6):8509-8521. PubMed ID: 30520029
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.